IN-SITU REFILLABLE OPHTHALMIC IMPLANT

• US 20100174272A1
• Filed: 12/18/2009
• Published: 07/08/2010
• Est. Priority Date: 01/02/2009
• Status: Abandoned Application

• Current Assignee: Alcon Research Limited (Nestle SA)
• Original Assignee: Alcon Research Limited (Nestle SA)
• Inventors: Weiner, Alan L.
• Application Number:
  US12/641,352
• Publication Number:
  US 20100174272A1
• Time in Patent Office: Days
• US Class Current: 604/891.100
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts

Abstract

The present invention is directed to an in-situ refillable ophthalmic implant having a refill port in communication with a reservoir and a release control mechanism. The present invention also relates to methods of forming and using the ophthalmic implant. Preferably, the control release mechanism include opening[s] providing for passive passage of pharmaceutical ophthalmic composition, particularly therapeutic agent, out of the reservoir, through the opening[s] and into the eye.

Claims

1. An in-situ refillable ophthalmic implant, comprising:

a body portion defining a reservoir;

a fill portion defining a fill port that is in fluid communication with the reservoir for allowing a pharmaceutical composition to be repeatedly located within the reservoir, the pharmaceutical composition including a therapeutic agent; and

a release control mechanism having at least one opening suitable for providing a controlled passive release of the pharmaceutical composition into the eye over an extended time period;

wherein, upon application of the implant to the eye, the release control mechanism is located within the eye and the fill portion is located outside the vitreous of the eye adjacent the sclera of the eye such that the fill port remains accessible outside of the vitreous of the eye.

2. An implant as in claim 1 wherein the body portion, the fill portion or a combination thereof define a contact surface that is disposed over the sclera upon application of the implant to the eye.

3. An implant as in claim 1 wherein the at least one opening of the release control mechanism includes multiple openings and wherein the multiple openings are sized to effectuate the controlled release of the therapeutic agent.

4. An implant as in claim 1 wherein the release control mechanism includes a door that can be opened and closed remotely to provide release of therapeutic agent to the vitreous.

5. An implant as in claim 1 wherein the body portion is elongated with a first end opposite a second end, the fill portion being located at the first end and the release control mechanism being located at the second end.

6. An implant as in claim 1 wherein the therapeutic agent lowers intraocular pressure within the eye.

7. An implant as in claim 1 wherein the control release mechanism includes a silicon disc through which the at least one opening extends.

8. An implant as in claim 1 wherein the body portion in overmolded onto the control release mechanism.

9. An implant as in claim 1 wherein the body portion, the fill portion or both are formed of a polymeric material.

10. An implant as in claim 1 further comprising a removable plug located within the port.

11. An implant as in claim 1 further comprising a diaphragm associated with the port, the diaphragm being penetrable by a needle or other elongated injection device for allowing filling of the reservoir through such injection device.

12. An implant as in claim 1 wherein, upon implantation, a cap portion of the implant is below the conjunctiva and resides upon the sclera.

13. An implant as in claim 1 wherein, upon implantation, the release control mechanism is located within the vitreous of the eye.

14. An implant as in claim 1 wherein the at least one opening has a cross-sectional area that is at least 8 microns² but is no greater than 4000 microns².

15. An implant as in claim 1 wherein the at least one opening has a cross-sectional area that is at least 15 microns² but is no greater than 2000 microns².

16. An in-situ refillable ophthalmic implant, comprising:

a body portion defining a reservoir;

a fill portion defining a fill port that is in fluid communication with the reservoir for allowing a pharmaceutical composition to be repeatedly located within the reservoir, the pharmaceutical composition including a therapeutic agent; and

a release control mechanism having multiple openings suitable for providing a controlled passive release of the pharmaceutical composition into the eye over an extended time period;

wherein, upon application of the implant to the eye, the release control mechanism is located within the vitreous of the eye and the fill portion is located outside the vitreous of the eye adjacent the sclera of the eye such that the fill port remains accessible outside of the vitreous of the eye; and

wherein the body portion, the fill portion or a combination thereof define a contact surface that is disposed over the sclera upon application of the implant to the eye; and

wherein the control release mechanism includes a silicon disc through which the multiple openings extend; and

wherein each of the multiple openings has a cross-sectional area that is at least 8 microns² but is no greater than 4000 microns².

17. An implant as in claim 16 wherein each of the multiple openings has a cross-sectional area that is at least 15 microns² but is no greater than 2000 microns².

18. An implant as in claim 17 wherein the body portion, the fill portion or both are formed of a polymeric material.

19. An implant as in claim 18 further comprising a diaphragm associated with the port, the diaphragm being penetrable by a needle or other elongated injection device for allowing filling of the reservoir through such injection device.

20. An implant as in claim 19 wherein the body portion is elongated with a first end opposite a second end, the fill portion being located at the first end and the release control mechanism being located at the second end.